Newsroom press releases

17/12/24 - 12:56

2025 Annual Calendar of Corporate Events (104.79 KB)

Download

11/11/24 - 7:38

Diasorin Announces 510(k) Submission for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (122.52 KB)

Products Molecular

Download

05/11/24 - 16:27

Diasorin reports another quarter with Revenues and Profitability in expansion, raising the Full-Year 2024 Revenue Guidance (238.01 KB)

Financial Data

Download

27/09/24 - 7:35

Diasorin announces 510(k) submission for LIAISON PLEX® Gram-Negative Blood Culture Assay (559.45 KB)

Products Molecular

Download

09/09/24 - 13:11

Diasorin launches the LIAISON® Streptococcus pneumoniae Ag Assay in all countries accepting the CE Mark (498.13 KB)

Products Immunodiagnostic

Download

05/09/24 - 11:17

DiaSorin S.p.A. - Update 2024 Annual Calendar of Corporate Events (99.93 KB)

Other

Download

04/09/24 - 11:36

Diasorin S.p.A. - Shareholders' Meeting September 4, 2024 (136.09 KB)

Other

Download

29/07/24 - 15:55

DIASORIN RAISES FULL-YEAR 2024 GUIDANCE AS A RESULT OF THE POSITIVE PERFORMANCE OF THE FIRST SEMESTER OF THE YEAR (606.06 KB)

Financial Data

Download

16/07/24 - 8:31

Diasorin receives FDA de-novo grant for the SIMPLEXA® C. auris Direct assay on the LIAISON® MDX instrument (546.76 KB)

Products Molecular

Download

05/06/24 - 5:07

Diasorin receives FDA 510(k) clearance for the LIAISON PLEX® Blood Culture Yeast Assay on the new multiplexing LIAISON PLEX® (693.98 KB)

Products Molecular

Download

16/05/24 - 19:56

Diasorin receives FDA 510(k) clearance for the updated syndromic panel NxTAG® Respiratory Pathogen Panel v2 (500.66 KB)

Products Molecular

Download

10/05/24 - 15:21

Q1 Revenues and Adjusted EBITDA in line with the high range of the FY’24 Guidance (689.42 KB)

Financial Data

Download

24/04/24 - 15:38

Shareholders' Meeting 2024 (159.72 KB)

Other

Download

16/04/24 - 8:20

Communication on total amount of voting rights (135.47 KB)

Other

Download

15/03/24 - 13:35

The Board of Directors of Diasorin SpA approves FY2023 Results; proposed ordinary dividend of € 1.15 per share (401.32 KB)

Financial Data

Download

13/03/24 - 10:23

Diasorin submits LIAISON PLEX® Yeast Blood Culture Assay for the LIAISON PLEX® system to the U.S. FDA (530.89 KB)

Products Molecular

Download

03/03/24 - 19:32

Diasorin receives FDA 510(K) clearance for its LIAISON PLEX® system together with the LIAISON PLEX® Respiratory Panel (150.83 KB)

Products Molecular

Download

25/01/24 - 7:48

Diasorin announces that it submitted the LIAISON® LymeDetect® to the U.S. Food and Drug Administration in December 2023 (507.38 KB)

Products Immunodiagnostic

Download

16/12/14 - 1:00

FDA approves 1,25 Vitamin D in the US market (239.73 KB)

Products Immunodiagnostic

Download

09/12/14 - 1:00

DiaSorin launches its first onco-hematology test on LIAISON Iam: the BCR-ABL (265.26 KB)

Products Immunodiagnostic

Download

14/11/14 - 1:00

The Board of Directors approves the results for Q3'14 (785.42 KB)

Financial Data

Download

07/10/14 - 2:00

DiaSorin launches the test for HIV HT on LIAISON (267.4 KB)

Products Immunodiagnostic

Download

18/09/14 - 2:00

DiaSorin launches the stool test for Adenovirus on LIAISON (251.93 KB)

Products Immunodiagnostic

Download

01/08/14 - 2:00

The Board of Directors approves the results for H1'14 (812.25 KB)

Financial Data

Download

22/07/14 - 2:00

DIASORIN CONFIRMS ITS ELIGIBILITY FOR THE PEA-PME (148.49 KB)

Financial Data

Download

30/06/14 - 2:00

DiaSorin launches the test for Herpes Simplex 1 and 2 on LIAISON IAM (250.1 KB)

Products Immunodiagnostic

Download

03/06/14 - 2:00

DiaSorin launches the test for Vitamin D 1,25 on LIAISON (265.57 KB)

Products Immunodiagnostic

Download

09/05/14 - 2:00

The Board of Directors approves the results for Q1'14 (573.05 KB)

Financial Data

Download

23/04/14 - 2:00

Shareholders' meeting approves FY Results 2013 (107.65 KB)

Financial Data

Download

06/03/14 - 1:00

The Board of Directors approves the results for FY'13 (753.73 KB)

Financial Data

Download

18/02/14 - 1:00

DiaSorin launches the new test for PTH on LIAISON (597.92 KB)

Products Immunodiagnostic

Download

11/02/14 - 1:00

DiaSorin launches the test for Rotavirus on stool sample (573.97 KB)

Products Immunodiagnostic

Download

28/01/14 - 1:00

DiaSorin extends its master agreement with Laboratory Corporation of America Holdings till 2018 (336.26 KB)

Acquisition / Partnership

Download

24/01/14 - 1:00

DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in China (579.02 KB)

Products Immunodiagnostic

Download

09/01/14 - 1:00

DiaSorin launches the test for Cytomegalovirus on LIAISON IAM (174.61 KB)

Products Immunodiagnostic

Download

Newsroom press releases

Select year

Newsroom press category

2025 Annual Calendar of Corporate Events (104.79 KB)

Diasorin Announces 510(k) Submission for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (122.52 KB)

Diasorin reports another quarter with Revenues and Profitability in expansion, raising the Full-Year 2024 Revenue Guidance (238.01 KB)

Diasorin announces 510(k) submission for LIAISON PLEX® Gram-Negative Blood Culture Assay (559.45 KB)

Diasorin launches the LIAISON® Streptococcus pneumoniae Ag Assay in all countries accepting the CE Mark (498.13 KB)

DiaSorin S.p.A. - Update 2024 Annual Calendar of Corporate Events (99.93 KB)

Diasorin S.p.A. - Shareholders' Meeting September 4, 2024 (136.09 KB)

DIASORIN RAISES FULL-YEAR 2024 GUIDANCE AS A RESULT OF THE POSITIVE PERFORMANCE OF THE FIRST SEMESTER OF THE YEAR (606.06 KB)

Diasorin receives FDA de-novo grant for the SIMPLEXA® C. auris Direct assay on the LIAISON® MDX instrument (546.76 KB)

Diasorin receives FDA 510(k) clearance for the LIAISON PLEX® Blood Culture Yeast Assay on the new multiplexing LIAISON PLEX® (693.98 KB)

Diasorin receives FDA 510(k) clearance for the updated syndromic panel NxTAG® Respiratory Pathogen Panel v2 (500.66 KB)

Q1 Revenues and Adjusted EBITDA in line with the high range of the FY’24 Guidance (689.42 KB)

Shareholders' Meeting 2024 (159.72 KB)

Communication on total amount of voting rights (135.47 KB)

The Board of Directors of Diasorin SpA approves FY2023 Results; proposed ordinary dividend of € 1.15 per share (401.32 KB)

Diasorin submits LIAISON PLEX® Yeast Blood Culture Assay for the LIAISON PLEX® system to the U.S. FDA (530.89 KB)

Diasorin receives FDA 510(K) clearance for its LIAISON PLEX® system together with the LIAISON PLEX® Respiratory Panel (150.83 KB)

Diasorin announces that it submitted the LIAISON® LymeDetect® to the U.S. Food and Drug Administration in December 2023 (507.38 KB)

FDA approves 1,25 Vitamin D in the US market (239.73 KB)

DiaSorin launches its first onco-hematology test on LIAISON Iam: the BCR-ABL (265.26 KB)

The Board of Directors approves the results for Q3'14 (785.42 KB)

DiaSorin launches the test for HIV HT on LIAISON (267.4 KB)

DiaSorin launches the stool test for Adenovirus on LIAISON (251.93 KB)

The Board of Directors approves the results for H1'14 (812.25 KB)

DIASORIN CONFIRMS ITS ELIGIBILITY FOR THE PEA-PME (148.49 KB)

DiaSorin launches the test for Herpes Simplex 1 and 2 on LIAISON IAM (250.1 KB)

DiaSorin launches the test for Vitamin D 1,25 on LIAISON (265.57 KB)

The Board of Directors approves the results for Q1'14 (573.05 KB)

Shareholders' meeting approves FY Results 2013 (107.65 KB)

The Board of Directors approves the results for FY'13 (753.73 KB)

DiaSorin launches the new test for PTH on LIAISON (597.92 KB)

DiaSorin launches the test for Rotavirus on stool sample (573.97 KB)

DiaSorin extends its master agreement with Laboratory Corporation of America Holdings till 2018 (336.26 KB)

DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in China (579.02 KB)

DiaSorin launches the test for Cytomegalovirus on LIAISON IAM (174.61 KB)

Price Sensitive